Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2016 1
2017 1
2020 1
2022 1
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

5 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean tian jingjing (227 results)?
Global intercompany assessment of ICIEF platform comparability for the characterization of therapeutic proteins.
Madren S, McElroy W, Schultz-Kuszak K, Boumajny B, Shu Y, Sautter S, Zhao HC, Schadock-Hewitt A, Chumsae C, Ball N, Zhang X, Rish K, Zhang S, Wurm C, Cai S, Bauer SP, Stella C, Zheng L, Roper B, Michels DA, Wu G, Kocjan B, Birk M, Erdmann SE, He X, Whittaker B, Song Y, Barrett H, Strozyk K, Jing Y, Huang L, Mhatre V, McLean P, Yu T, Yang H, Mattila M. Madren S, et al. Electrophoresis. 2022 May;43(9-10):1050-1058. doi: 10.1002/elps.202100348. Epub 2022 Mar 18. Electrophoresis. 2022. PMID: 35245390
A historical controlled study of domestic trastuzumab and pertuzumab in combination with docetaxel for the neoadjuvant treatment of early HER2-positive breast cancer.
Xu D, Wu J, Yu J, Yang Y, Wen X, Yang J, Wei H, Xu X, Li Y, Yang L, Wang L, Wang Y, Ma W, Li N. Xu D, et al. Front Oncol. 2024 Feb 9;14:1281643. doi: 10.3389/fonc.2024.1281643. eCollection 2024. Front Oncol. 2024. PMID: 38406813 Free PMC article.
Docetaxel, TQB211, and TQB2440 were all developed by Chiatai Tianqing. The primary endpoint was the complete pathological response (pCR) in the breast, and the secondary endpoint was cardiac safety. ...
Docetaxel, TQB211, and TQB2440 were all developed by Chiatai Tianqing. The primary endpoint was the complete pathological response (p …